In 2020, approximately 3.3 million men were living with prostate cancer in the United States.1 Screening recommendations, risk classification, and treatment approaches are constantly evolving and more than ever before, guidelines emphasize shared decision-making and quality of life. It is therefore imperative that pharmacists have the knowledge and tools to help patients navigate the screening and treatment choices. This Pharmacy Today continuing education article will review current screening recommendations, pharmacotherapy, recent landmark trials and updates to national prostate cancer guidelines.